|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
neuraminidase inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Tamiflu
|
|
gptkbp:clinical_trial
|
gptkb:H1_N1_influenza
gptkb:influenza_B
Phase III
80% to 90%
seasonal influenza
H3 N2 influenza
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to oseltamivir
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
gptkb:beer
suspension
|
|
gptkbp:duration
|
5 days
10 days for prophylaxis
|
|
gptkbp:effective_date
|
gptkb:1999
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:beer
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oseltamivir
|
|
gptkbp:indication
|
prevention of influenza
|
|
gptkbp:ingredients
|
gptkb:oseltamivir_phosphate
C13 H18 N2 O4 S
|
|
gptkbp:interacts_with
|
live attenuated influenza vaccine
probenecid
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
J05 A H02
|
|
gptkbp:is_used_for
|
treatment of influenza
|
|
gptkbp:lifespan
|
6 to 10 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Tamiflu
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
inhibits viral replication
prodrug
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
headache
nausea
vomiting
diarrhea
neuropsychiatric events
|
|
gptkbp:treatment
|
reduces duration of symptoms
reduces risk of complications
effective if started within 48 hours of symptom onset
|
|
gptkbp:type_of
|
198470-85-8
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
4
|